| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 203.99 | 52.5% |
| Total Income | 217.67 | 50.5% |
| Expenditure | 160.43 | 36.9% |
| PBT | 57.24 | 69.1% |
| Net Profit | 44.06 | 68.6% |
| OPM | 30.10% | 14.20pp |
| NPM | 20.24% | 11.72pp |
| EPS | 4.21 | 68.6% |
Concord Biotech Ltd Reports FY 2024-2025 Financial Results with 78% Turnover from API Manufacturing
13 Aug 2025 · 13 Aug 2025, 02:43 pm
Summary
Concord Biotech Ltd, a research-driven biopharmaceutical company, has reported its financial results for FY 2024-2025. The company's turnover is primarily driven by API manufacturing, contributing to 78% of the total turnover. The company operates in three strategic verticals: Active Pharmaceutical Ingredients (API), Finished Formulations, and Contract Research & Manufacturing Services (CRAMS).
Key Highlights
- 1
FY 2024-2025 financial results reported
- 2
78% turnover from API manufacturing
- 3
Operates in three strategic verticals
- 4
Robust portfolio catering to over 250 customers across more than 70 countries
Management Comments
Not specified in the document
Not available in the document
Informational and educational content only. Not investment advice.